ReviewJACS Au2026
Carrier-Free Enzyme Immobilization for High-Density Catalytic Architectures in Flow Biocatalysis.
Review in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carrier-free enzyme immobilization has become a central design concept for constructing high-density catalytic architectures in flow biocatalysis. This Perspective discusses the evolution of such materials from early cross-linked enzyme aggregates and crystals to biologically derived inclusion bodies, all-enzyme hydrogels (AEHs), and genetically encoded protein crystals. These carrier-free systems achieve high enzyme loadings, enhanced stability, and improved cofactor retention, thereby enabling continuous processing under mild conditions. Among them, AEHs currently provide the most versatile experimental platform, combining high catalytic density with tunable porosity and mechanical flexibility that favor mass transport and integration into microstructured reactors. Genetically encoded crystalline assemblies complement this development through molecular precision and robustness. The article further highlights emerging trends in automation and data-driven reactor control, including the use of inline analytics for autonomous optimization, as well as the growing importance of standardized data management following the FAIR (findable, accessible, interoperable, reusable) principles. Together, these advances outline a path toward precision biocatalysis, where material design, reactor engineering, and digital control converge to enable sustainable and reproducible enzyme-driven manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.